1.38 USD
↘ 0.02 (1.43%)AT CLOSE (11:59 AM EDT)
Akebia Therapeutics, Inc.
AKBANASDAQ • USD
1.39
↗ 0.01 (0.36%)
POST MARKET (AS OF 07:51 PM EDT)
Post Market
AS OF 07:51 PM EDT
1.39
↗ 0.01 (0.36%)
Market: CLOSED
Shares of Akebia Therapeutics, Inc. (AKBA) are trading at $1.39. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place AKBA at a fair price relative to peers.
Technical & fundamental data as of Jul 13, 2026.
Open?$1.37
High?$1.39
Low?$1.34
Prev. Close?$1.40
Volume?3.4M
Avg. Volume?5.8M
VWAP?$1.37
Rel. Volume?0.58x
Bid / Ask
Bid?$1.36 × 300
Ask?$1.38 × 1.2K
Spread?$0.02
Midpoint?$1.37
Valuation & Ratios
Market Cap?370.2M
Shares Out?268.3M
Float?256.1M
Float %?95.5%
P/E Ratio?N/A
P/B Ratio?13.52
EPS?-$0.08
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Employees
194
Market Cap
375.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-03-20
Address
245 FIRST STREET
CAMBRIDGE, MA 02142
Phone: 617-871-2098
CAMBRIDGE, MA 02142
Phone: 617-871-2098
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?0
Momentum?10
Short Sent.?56
Piotroski F-Score?1/9Weak
Altman Z-Score?-4.95Distress
Confidence?60%Moderate
Short InterestElevated
Short % of Float?7.49%Elevated
Short Interest?19.2M
Days to Cover?2.7
Free Float256.1M
Avg Daily Volume7.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.40Adequate
Quick Ratio?1.33Adequate
Cash Ratio?0.94Adequate
Debt/Equity?1.79High
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score73/100
P/E?N/A▾
P/B?13.52HIGH▾
Peers100
S&P14
P/S?1.59CHEAP▾
Peers100
S&P77
P/FCF?6.2CHEAP▾
Peers100
S&P97
EV/EBITDA?39.0HIGH▾
Peers100
S&P6
EV/Sales?1.10CHEAP▾
Peers100
S&P90
Returns & Efficiency
ROE?-74.9%WEAK▾
S&P3
ROA?-5.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$60.0M
Enterprise Value?$256.4M
Fundamentals ratios updated end of day